BACKGROUND: Human rhinoviruses (HRVs) are the most common cause of asthma exacerbations. In airway epithelial cells, the primary site of HRV infection, decreased production of interferons (IFNs) may result in greater susceptibility to HRV and worsened symptoms. Thus, exogenous IFN could supplement the innate immune response and provide a treatment for virus-induced asthma exacerbations. Furthermore, the effects of exogenous IFN could be type specific in part because of the cellular distribution of type 1 and type 2 IFN receptors. OBJECTIVE: To investigate the effects of exogenous IFNs on HRV replication in bronchial epithelial cells. METHODS: Frozen stocks of primary human bronchial epithelial cells from healthy donors were cultured in monolayers; pretreated (24 hours) with 0.1-ng/mL, 1-ng/mL, or 10-ng/mL doses of IFN-α, -β, -λ1, or -λ2; and infected with HRV-1A. Viral replication was quantified using real-time reverse transcription-polymerase chain reaction, and cytokine and chemokine secretion 24 hours after infection was measured by multiplex enzyme-linked immunosorbent assay. RESULTS: Compared with untreated samples, IFN-α, IFN-β, IFN-λ1, and IFN-λ2 (0.1 ng/mL) significantly reduced HRV replication after high- (P < .02) and low-dose inoculation (P < .05). Similar effects were seen in 1-ng/mL and 10-ng/mL doses of IFN, where HRV replication was significantly decreased in both high- (P < .001) and low-dose inoculation (P < .001). Treatment with IFNs also enhanced HRV-induced IFN-γ-induced protein 10 secretion (P < .001). Finally, treatment with either IFN-λ1 or IFN-λ2 significantly increased HRV-induced secretion of RANTES (regulated on activation, normal T-expressed, and presumably secreted) (P < .05) but not IL-1β or vascular endothelial growth factor. CONCLUSION: These findings suggest that exogenous IFNs, IFN-λ1 in particular, warrant further study as a potential therapy for virus-induced asthma exacerbations.
BACKGROUND: Human rhinoviruses (HRVs) are the most common cause of asthma exacerbations. In airway epithelial cells, the primary site of HRV infection, decreased production of interferons (IFNs) may result in greater susceptibility to HRV and worsened symptoms. Thus, exogenous IFN could supplement the innate immune response and provide a treatment for virus-induced asthma exacerbations. Furthermore, the effects of exogenous IFN could be type specific in part because of the cellular distribution of type 1 and type 2 IFN receptors. OBJECTIVE: To investigate the effects of exogenous IFNs on HRV replication in bronchial epithelial cells. METHODS: Frozen stocks of primary human bronchial epithelial cells from healthy donors were cultured in monolayers; pretreated (24 hours) with 0.1-ng/mL, 1-ng/mL, or 10-ng/mL doses of IFN-α, -β, -λ1, or -λ2; and infected with HRV-1A. Viral replication was quantified using real-time reverse transcription-polymerase chain reaction, and cytokine and chemokine secretion 24 hours after infection was measured by multiplex enzyme-linked immunosorbent assay. RESULTS: Compared with untreated samples, IFN-α, IFN-β, IFN-λ1, and IFN-λ2 (0.1 ng/mL) significantly reduced HRV replication after high- (P < .02) and low-dose inoculation (P < .05). Similar effects were seen in 1-ng/mL and 10-ng/mL doses of IFN, where HRV replication was significantly decreased in both high- (P < .001) and low-dose inoculation (P < .001). Treatment with IFNs also enhanced HRV-induced IFN-γ-induced protein 10 secretion (P < .001). Finally, treatment with either IFN-λ1 or IFN-λ2 significantly increased HRV-induced secretion of RANTES (regulated on activation, normal T-expressed, and presumably secreted) (P < .05) but not IL-1β or vascular endothelial growth factor. CONCLUSION: These findings suggest that exogenous IFNs, IFN-λ1 in particular, warrant further study as a potential therapy for virus-induced asthma exacerbations.
Authors: D H Smith; D C Malone; K A Lawson; L J Okamoto; C Battista; W B Saunders Journal: Am J Respir Crit Care Med Date: 1997-09 Impact factor: 21.405
Authors: Jason C L Spurrell; Shahina Wiehler; Raza S Zaheer; Scherer P Sanders; David Proud Journal: Am J Physiol Lung Cell Mol Physiol Date: 2005-03-11 Impact factor: 5.464
Authors: M K Schroth; E Grimm; P Frindt; D M Galagan; S I Konno; R Love; J E Gern Journal: Am J Respir Cell Mol Biol Date: 1999-06 Impact factor: 6.914
Authors: Anne G Mosser; Rose Vrtis; Lacinda Burchell; Wai-Ming Lee; Claire R Dick; Elizabeth Weisshaar; Diane Bock; Cheri A Swenson; Richard D Cornwell; Keith C Meyer; Nizar N Jarjour; William W Busse; James E Gern Journal: Am J Respir Crit Care Med Date: 2004-12-10 Impact factor: 21.405
Authors: Sandy R Durrani; Daniel J Montville; Allison S Pratt; Sanjukta Sahu; Mark K DeVries; Victoria Rajamanickam; Ronald E Gangnon; Michelle A Gill; James E Gern; Robert F Lemanske; Daniel J Jackson Journal: J Allergy Clin Immunol Date: 2012-07-04 Impact factor: 10.793
Authors: Peter A B Wark; Sebastian L Johnston; Fabio Bucchieri; Robert Powell; Sarah Puddicombe; Vasile Laza-Stanca; Stephen T Holgate; Donna E Davies Journal: J Exp Med Date: 2005-03-21 Impact factor: 14.307
Authors: Peter W Heymann; Holliday T Carper; Deborah D Murphy; Thomas A E Platts-Mills; James Patrie; Anne P McLaughlin; Elizabeth A Erwin; Marcus S Shaker; Martha Hellems; Jehanna Peerzada; Frederick G Hayden; Tina K Hatley; Rachel Chamberlain Journal: J Allergy Clin Immunol Date: 2004-08 Impact factor: 10.793
Authors: Ellen F Foxman; James A Storer; Megan E Fitzgerald; Bethany R Wasik; Lin Hou; Hongyu Zhao; Paul E Turner; Anna Marie Pyle; Akiko Iwasaki Journal: Proc Natl Acad Sci U S A Date: 2015-01-05 Impact factor: 11.205
Authors: D A Loisel; G Du; T S Ahluwalia; C J Tisler; M D Evans; R A Myers; R E Gangnon; E Kreiner-Møller; K Bønnelykke; H Bisgaard; D J Jackson; R F Lemanske; D L Nicolae; J E Gern; C Ober Journal: Clin Exp Allergy Date: 2016-01 Impact factor: 5.018
Authors: Nurlan Dauletbaev; Mithun Das; Maria Cammisano; He Chen; Sareen Singh; Cora Kooi; Richard Leigh; Trevor Beaudoin; Simon Rousseau; Larry C Lands Journal: PLoS One Date: 2015-11-23 Impact factor: 3.240